Deerfield Management Company, L.P. (Series C) Revolution Medicines, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.04 Billion
- Q4 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Revolution Medicines, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 3,258,332 shares of RVMD stock, worth $135 Million. This represents 3.53% of its overall portfolio holdings.
Number of Shares
3,258,332
Previous 2,912,692
11.87%
Holding current value
$135 Million
Previous $132 Million
7.99%
% of portfolio
3.53%
Previous 2.45%
Shares
12 transactions
Others Institutions Holding RVMD
# of Institutions
299Shares Held
179MCall Options Held
920KPut Options Held
1.06M-
Vanguard Group Inc Valley Forge, PA17.1MShares$707 Million0.01% of portfolio
-
Black Rock Inc. New York, NY13.4MShares$554 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA13.2MShares$548 Million3.09% of portfolio
-
Wellington Management Group LLP Boston, MA10.8MShares$447 Million0.09% of portfolio
-
Janus Henderson Group PLC London, X09.48MShares$392 Million0.22% of portfolio
About Revolution Medicines, Inc.
- Ticker RVMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,697,600
- Market Cap $3.63B
- Description
- Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...